Longitude Capital — 2014 Investments

5 investments dated 2014 · listed companies and verified rows first · show all

Civitas Therapeuticscivitastherapeutics.comAug 2014 · $20M

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in

BoardROB HOPFNER(Director)in

Co-investorsCanaan Partners Sofinnova Ventures Bay City Capital Fountain Healthcare Partners OrbiMed RA Capital

Esperion Therapeuticsesperion.comJun 2014

Biopharma developing HDL-C regulating therapies; listed 2000.

BiotechAnn Arbor, US

Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)

BoardDaniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)inPatrick Enright(Director)in

Co-investorsAisling Capital Alta Partners Arboretum Ventures ARCHIMED Japan Asset Management Company Canaan Partners +5 more

Lumena Pharmaceuticals 𝕏Mar 2014acquired by Shire

Acquired by Shire in 2014 (now part of Takeda).

BiotechMedical DevicesDurham, US

John McKearn(Director)Edward E. Greene(Director)Rosina Maar Pavia(Director)Ford S. Worthy(Executive Officer)Michael Grey(Executive Officer, Director)

Co-investorsFrazier Life Sciences Oberland Capital Pappas Capital RiverVest Venture Partners Sanofi Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AqueSys Cardero Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.